Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Don't Miss

BIO in 30: A new biotech from Gates, Bradner on data science, & bienvenue à Cambridge

  • Helen Branswell
  • Adam Feuerstein
  • Damian Garde

By Helen Branswell , Adam Feuerstein and Damian Garde June 7, 2018

Reprints

BIO in 30: A new biotech from Gates, Bradner on data science, & bienvenue à Cambridge

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Authors Reprints

Helen Branswell

Helen Branswell

Senior Writer, Infectious Diseases

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Post News.

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

I helped write the manual for diagnosing mental illness.…
I helped write the manual for diagnosing mental illness. Donald Trump doesn’t meet the criteria
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
New research may give geneticists a long-sought tool: a…
New research may give geneticists a long-sought tool: a targeted protein delivery device
Under pressure, biotech and pharma grapple with how to…
Under pressure, biotech and pharma grapple with how to take climate action
With new study data, Intra-Cellular could expand use of…
With new study data, Intra-Cellular could expand use of approved mood-disorder treatment

Recommended Stories